Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) [Prevnar 13] is indicated for active immunization to prevent invasive disease and otitis media caused by Streptococcus pneumoniae in various age groups.
• The information was derived from a systematic review of 16 studies.
• Prevnar 13 shows higher efficacy and effectiveness compared to PPSV23, with PCV13 demonstrating consistent results across different studies for both IPD (Invasive Pneumococcal Disease) and PP (Pneumococcal Pneumonia).
• In infants under two years old, Prevnar 13 generally has higher IgG responses for certain serotypes compared to PCV10, indicating better immunogenicity.
• For children under five years old, the effectiveness of Prevnar 13 against otitis media ranges between approximately 2.2% to 68%, showing variability based on age and setting but still providing significant protection.
• Vaccine failures in using Prevnar 13 are mainly associated with serotypes such as 19A, 3, and 19F; however, it remains highly effective overall despite these specific challenges.
• Co-administration studies indicate that co-administering Prevnar with other vaccines does not significantly increase adverse events, suggesting it is safe when used alongside other vaccinations.
• Compared to other pneumococcal vaccines like PCV10 or PHiD-CV, mixed schedules involving Prevnar are safe, effective, and show high levels of immunogenicity against IPD.